Document Detail


Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study.
MedLine Citation:
PMID:  21036549     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
AIM: To assess the coronary heart disease (CHD) risk and prevalence of the metabolic syndrome (MS) in patients with schizoaffective disorder (SD) receiving antipsychotics.
METHODS: Patients meeting DSM-IV criteria for SD and receiving antipsychotic treatment were recruited in a retrospective, cross-sectional, multicenter study (the CLAMORS study). MS was defined as at least three of the following components: waist circumference greater than 102 cm (men)/greater than 88 cm (women); serum triglycerides greater or equal to 150 mg/dl; HDL cholesterol less than 40 mg/dl (men)/less than 50 mg/dl (women); blood pressure greater or equal to 130/85 mmHg; fasting blood glucose greater or equal to 110 mg/dl. The 10-year CHD risk was assessed by the Systematic coronary risk evaluation (SCORE) (cardiovascular mortality) and Framingham (any cardiovascular event) functions. Clinical severity was assessed using the PANSS and CGI-S scales.
RESULTS: A total of 268 valuable patients with SD (127 men, 48.1%), 41.9±12.3 years (mean±S.D.), were analyzed. The 10-year overall cardiovascular mortality and CV-event risk were 0.8±1.6 (SCORE) and 6.5±6.8 (Framingham), respectively. A high/very high risk of any CV event (Framingham≥10%) was associated with severity [CGI-S=3-4; OR: 4.32 (1.15-16.26), P=0.03)]. MS was present in 26.5% (95%CI: 21.2-31.8) of subjects, without gender differences, but significantly associated with patient's impression of severity: CGI=3-4; OR=1.90 (0.83-4.36), and CGI=5-7; OR=3.13 (1.06-9.24), P=0<0.001, and age [OR=1.91 (1.09-3.34), P<0.024)].
CONCLUSIONS: CHD risk and MS prevalence were high among patients with SD, being MS prevalence associated with age and severity of disease.
Authors:
J Bobes; C Arango; P Aranda; R Carmena; M Garcia-Garcia; J Rejas;
Related Documents :
12900679 - Sedentary lifestyle, poor cardiorespiratory fitness, and the metabolic syndrome.
21625889 - Validation of the adherence evaluation of osteoporosis treatment (adeos) questionnaire ...
16514099 - Influence of metabolic syndrome and general obesity on the risk of ischemic stroke.
21847119 - Body mass index in early and middle-late adulthood and risk of localised, advanced and ...
21971329 - Risk factors for systemic reactions to allergen immunotherapy.
17935959 - Factors associated with the metabolic syndrome in a national sample of youths: caspian ...
21752159 - Intracranial haemorrhage in the italian population of haemophilia patients with and wit...
20605479 - Ldl-containing immune complexes in the dcct/edic cohort: associations with lipoprotein ...
18976309 - Strabismus and employment: the opinion of headhunters.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-30
Journal Detail:
Title:  European psychiatry : the journal of the Association of European Psychiatrists     Volume:  27     ISSN:  1778-3585     ISO Abbreviation:  Eur. Psychiatry     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111820     Medline TA:  Eur Psychiatry     Country:  France    
Other Details:
Languages:  eng     Pagination:  267-74     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Masson SAS. All rights reserved.
Affiliation:
Medicine Department, Psychiatry Area, University of Oviedo, Centro de Investigación Biomédica en Red de Salud Mental CIBERSAM, C/Julián Clavería, 6, 33006 Oviedo (Asturias), Spain. bobes@uniovi.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Investigator
Investigator/Affiliation:
L Albaiges / ; M O Alday / ; M Alonso / ; P Álvarez / ; S Álvarez / ; G Alzate / ; J B Anguiano / ; C Antón / ; E Aragues / ; F Asensio / ; C Bardolet / ; J Barragán / ; J A Bellido / ; R Bordas / ; J Busto / ; J Cadevall / ; J Cañete / ; I Capllonch / ; C Carmona / ; E Carrasco / ; A Carrillo / ; C Castillo / ; E R Chinea / ; M Cleris / ; C De Dios / ; M A De Uña / ; N Díaz / ; J R Doménech / ; M Ducaju / ; M Echeveste / ; A Fernández / ; A Fernández-Cuevas / ; R Fernández-Villamor / ; J L Figuerido / ; J Fluvia / ; J I Franch / ; F Galán / ; I García / ; J García / ; M P García-Portilla / ; P Gil / ; J Gómez-Trigo / ; F A González / ; G González / ; P González / ; T González / ; M González-Quirós / ; O Graizer / ; C Hernández / ; J L Hernández / ; C Iglesias / ; J Irurita / ; M I Justo / ; M Karim / ; L M Larrazabal / ; J Lizarraga / ; F M Lojo / ; I López / ; J López / ; L López / ; M Loro / ; E Martín / ; F Martín / ; A Martínez / ; J J Martínez de Morentín / ; J L Martínez / ; J M Martínez / ; M Martínez / ; R Martínez / ; G Medina / ; J L Medina / ; P Megía / ; J I Mendezona / ; M J Merino / ; M Messays / ; J M Misiego / ; J M Mongil / ; A L Montejo / ; J M Montes / ; M A More / ; L Moyano / ; M C Natividad / ; L Pacheco / ; D J Palao / ; A L Palomo / ; G Parramón / ; G Pascual / ; A Pastor / ; F J Pastor / ; E Peralta / ; E Pérez / ; N Prieto / ; E Rodríguez / ; J C Rodríguez / ; A Roig / ; P Rojano / ; T Rubio / ; F C Ruiz / ; J M Ruiz / ; A Salesansky / ; M C Salgado / ; G I San Narciso / ; J M Sánchez / ; J Sanz / ; P Shabiaga / ; J R Silveira / ; P A Sopelana / ; J A Soto / ; E Sotomayor / ; F Teba / ; M Valdelomar / ; J R Valle / ; F J Vicente / ; D Villagran / ; A Villamor /

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increasing escitalopram dose is associated with fewer discontinuations than switch or combination ap...
Next Document:  Evaluation of side effects using the BARS, SAS and AIMS in pediatric psychopharmacologic studies.